We profiled Æterna Zentaris (AEZS) stock as a highly speculative investment opportunity at around $.44. AEZS shares almost doubled in value for the last six weeks and still on their way to over a dollar. Market favored Æterna’s stock with Roth Capital initiation a “Buy” share/price target of $1.75 and even more price goal expectations from the […]
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced on June 28th that its Japanese partner Yakult Honsha (“Yakult”) (Tokyo: 2267) has initiated a Phase 1 trial in multiple myeloma, a form of blood cancer, with perifosine, the Company’s oral Akt/PI3K inhibitor drug. Yakult, who are sponsoring and conducting this trial in Japan, reported that a first patient […]
